| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Eliem Therapeutics, Inc. | Chief Operating Officer | Restricted Stock Units | 77,500 | $618,450 | $7.98 | 26 Aug 2024 | Direct |
| Climb Bio, Inc. | Chief Operating Officer | Stock Option (Right to Buy) | 500,000 | 13 Jan 2025 | Direct | ||
| Compass Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 30,000 | 18 Feb 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| CLYM | Climb Bio, Inc. | 13 Jan 2025 | 1 | $0 | 4 | Chief Operating Officer | 15 Jan 2025, 16:15 |
| ELYM | Eliem Therapeutics, Inc. | 26 Aug 2024 | 2 | $0 | 4 | Chief Operating Officer | 26 Aug 2024, 17:47 |
| ELYM | Eliem Therapeutics, Inc. | 26 Aug 2024 | 0 | $0 | 3 | Chief Operating Officer | 26 Aug 2024, 17:40 |
| CMPX | Compass Therapeutics, Inc. | 18 Feb 2022 | 1 | $0 | 4 | Director | 23 Feb 2022, 16:45 |